NasdaqGS:LIVNMedical Equipment
LivaNova (LIVN): Reassessing Valuation After KeyBanc’s Overweight Initiation and Growth Outlook
KeyBanc just kicked off coverage on LivaNova (LIVN) with an Overweight call, highlighting what it sees as underappreciated growth from capital equipment cycles, share gains, better clinical data, and upcoming aura6000 commercialization.
See our latest analysis for LivaNova.
The upbeat initiation comes as LivaNova’s share price has climbed 34.66 percent year to date and delivered a 33.69 percent total shareholder return over the past year. This suggests momentum is building as investors...